Wednesday, April 24, 2013

Votrient meets primary endpoint in Ovarian Cancer

In its  Q1 2013 earnings press release, GSK has announced that Votrient has met its primary endpoint in ovarian cancer. The data is currently in-house and would be presented at an upcoming conference. GSK also announced filing of Votrient for renal cancer in Japan.

GSK also announced that Tykerb did not meet the primary endpoint in Gastric cancer.
Enter your email address:


Delivered by FeedBurner